Diffuse Large B-cell Lymphoma DLBCL (relapsed/refractory)

Indication: Diffuse Large B-cell Lymphoma
Title: DLBCL/SADAL: A Phase 2b Open-label Study of selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Drug: selinexor

SADAL is an open label, Phase 2b study evaluating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.

Please visit clinicaltrials.gov for more information about this study

This trial is for selinexor.

Rights

XPOVIO (selinexor) is approved in the U.S. for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy

Phase I	Phase II	Phase III
Approved